Elaine 1: Las Vs Fulv In La Er+/Her2- Mbc Esr1M + Disease Progression On Ai And Cdk4/6I Inhibitors

ELAINE 1: LAS vs fulv in la ER+/HER2- mBC ESR1m + disease progression on AI and CDK4/6i inhibitors

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial

Lasofoxifene shows promise for women with ESR1-mutated mBC

ELAINE 1: ESR1 mutations in ctDNA from ER+/HER2- mBC treated with lasofoxifene or fulvestrant

HR+ Breast Cancer: Differences Between CDK4/6 Inhibitors

1L use of CDK4/6i + ET shows no clinically meaningful PFS compared to 2L use in HR+, HER2- ABC

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancer

Mafalda Oliveira, SABCS 2022: Camizestrant vs fulvestrant for advanced ER+ HER2- breast cancer

Touch Medical Media

Dr. Vidal on the Use of CDK4/6 Inhibitors in HER2+ Breast Cancer

ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer

Dr. Rugo on Rationale for the ELAINE Study in ESR1-Mutated ER+/HER2- Breast Cancer

Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer

Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impacts

Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer

ER+/HER2+ Metastatic Breast Cancer

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts

Phase I/II study of a novel SERCA in ER+ HER2- BC

ESR1 Mutation: The Need for & Role of Testing in ER+/ HER2- Advanced or Metastatic Breast Cancer

COR2ED The Heart of Medical Education

Dr. Shaheenah Dawood – ESMO 2022 – Clinical trial updates in breast cancer management

Karger Publishers

New Breast Cancer Clinical Trial: Imlunestrant for Breast Cancer

Power Life Sciences